TY  - JOUR
AU  - May, Verena
AU  - Berchtold, Susanne
AU  - Berger, Alexander
AU  - Venturelli, Sascha
AU  - Burkard, Markus
AU  - Leischner, Christian
AU  - Malek, Nisar P
AU  - Lauer, Ulrich M
TI  - Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus.
JO  - Oncology letters
VL  - 18
IS  - 5
SN  - 1792-1082
CY  - Athens
PB  - Spandidos Publ.
M1  - DKFZ-2020-00068
SP  - 5534-5542
PY  - 2019
N1  - LA:L801
AB  - Oncolytic virotherapy with vaccine viruses employs replicative vectors, which quite selectively infect tumor cells leading to massive virus replication followed by subsequent profound tumor cell death (oncolysis). Measles vaccine virus (MeV) has already shown great oncolytic activity against different types of cancers, including pancreatic cancer. Gemcitabine is a first line chemotherapeutic drug used for pancreatic cancer in palliative treatment plans. Furthermore, this drug can be used to induce senescence, a permanent cell cycle arrest, in tumor cells. In our preclinical work, three well-characterized immortalized human pancreatic cancer cell lines were used to investigate the combinatorial effect of MeV-based virotherapy together with the chemotherapeutic compound gemcitabine. Viability assays revealed that the combination of only small amounts of MeV together with subtherapeutic concentrations of gemcitabine resulted in a tumor cell mass reduction of >50
LB  - PUB:(DE-HGF)16
C6  - pmid:31612061
C2  - pmc:PMC6781561
DO  - DOI:10.3892/ol.2019.10901
UR  - https://inrepo02.dkfz.de/record/148910
ER  -